1. Kaplan MM. Primary biliary cirrhosis. New England Journal of Medicine 1987; 316:521-528.

2. Poupon R, Poupon RE. Primary biliary cirrhosis. In: Zakim D, Boyer TD, eds. Hepatology. A textbook of Liver Disease. Third Edition. Philadelphia, London, Toronto, Montreal, Sydney, Tokyo: W.B. Saunders Company, 1996:1329-1365.

3. Gershwin ME, Rowley M, Davis PA, Leung P, Coppel RL, Mackay IR. Molecular biology of the 2-oxo-acid dehydrogenase complexes and anti-mitochondrial antibodies. In: Boyer JL, Ockner RK, eds. Progress in Liver Diseases: WB Saunders Company Publ., 1992:47-61.

4. Worman HJ, Courvalin JC. Autoantibodies against nuclear envelope proteins in liver disease. Hepatology 1991; 14:1269-1279.

5. Szostecki C, Will H, Netter HJ, Guldner HH. Autoantibodies to the nuclear Sp100 protein in primary biliary cirrhosis and associated diseases: epitope specificity and immunoglobulin class distribution. Scandinavian Journal of Immunology 1992; 36:555-564.

6. Neuberger J, Thomson R. PBC and AMA — What is the connection? . Hepatology 1999; 29:271-276.

7. Poupon R, Chazouillères O, Balkau B, Poupon RE, and the UDCA-PBC Group. Clinical and biochemical expression of the histopathological lesions of primary biliary cirrhosis. Journal of Hepatology 1999; 30:408-412.

8. Chazouillères O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis – autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998; 28:296-301.

9. Ludwig J, Wiesner RH, LaRusso NF. Idiopathic adulthood ductopenia. A cause of chronic cholestatic liver disease and biliary cirrhosis. Journal of Hepatology 1988; 7:193-199.

10. Bergasa NV, Jones EA. The pruritus of cholestasis: potential pathogenic and therapeutic implications of opioids. Gastroenterology 1995; 108:1582-1588.

11. Mahl TC, Shockcor W, Boyer JL. Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. Journal of Hepatology 1994; 20:701-713.

12. Bonnand A-M, Heathcote EJ, Lindor KD, Poupon RE. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. Hepatology 1999; 29:39-43.

13. Poupon R, Chrétien Y, Poupon RE, Ballet F, Calmus Y, Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987; 1:834-836.

14. Rodrigues CM, Fan G, Ma X, Kren BT, Steer CJ. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. Journal of Clinical Investigation 1998; 101:2790-2799.

15. Poupon R, Poupon RE. Ursodeoxycholic acid therapy of chronic cholestatic conditions in adults and children. Pharmacology and Therapeutics 1995; 66:1-15.

16. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113:884-890.

17. Poupon RE, Balkau B, Eschwège E, Poupon R, and the UDCA-PBC Study Group. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. New England Journal of Medicine 1991; 324:1548-1554.

18. Poupon RE, Poupon R, Balkau B, and the UDCA-PBC Study Group. Ursodiol for the long-term treatment of primary biliary cirrhosis. New England Journal of Medicine 1994; 330:1342-1347.

19. Markus BH, Dickson ER, Grambsch PM, et al. Efficacy of liver transplantation in patients with primary biliary cirrhosis. New England Journal of Medicine 1989; 320:1709-1713.